BridgeMD
New treatment option for Glioma Glioblastoma Multiforme
Official title Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
ClinicalTrials.gov ID: NCT06687681
What this study is testing
What is NK cell therapy?
NK cell therapy is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for glioma glioblastoma multiforme.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Gliomas are the most common malignant brain tumors, which are often associated with high-grade tumors characterized by an inferior prognosis and low patient survival rates in both children and adults. Surgical removal and tumor resection are the primary treatment approaches for gliomas.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 3 to 70
You may be able to join if
- New diagnosed patients with grade 3 or 4 brain tumor, based on WHO classification, which are included in the one of the following conditions...
You likely can't join if
- Evidence of radio necrosis in MRI or MRS Intolerance of new treatment due to emergency condition History of other malignancies History of any...
The study team makes the final eligibility decision.
Where it's taking place
- Tehran, Iran
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 3 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tehran, Iran. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.